Hinge Health (HNGE) Q3 2026 Earnings Call Transcript
Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.
How this was made

The 30-second read
Why it matters
The earnings beat and margin expansion could attract growth‑oriented investors, but integration of new programs carries risk.
Market read
Strong earnings may boost Hinge Health stock; limited spillover to broader health‑tech sector.
What to watch
Execution risk of new Migraine and GI programs and integration costs.
Background
Hinge Health is a digital health company focusing on musculoskeletal, migraine, and gastrointestinal care.
Ticker impact
Q3 2026 earnings call disclosed revenue of $235M (+52% YoY) and operating margin of 33%, a fresh primary earnings report.
likely upward pressure as investors price in robust growth and margin expansion
First‑time disclosure of significantly higher revenue and margins; market may react positively.
Market effects
Highlights growth potential in digital musculoskeletal health and tele‑rehab sector.
U.S. digital health stocks may see modest lift.
Limited to health‑tech niche; no broad market effect.
Counterpoint
Valuation may already price in growth; earnings beat could be already baked in.
Key entities
- CompanyHinge Health
Digital health provider reporting Q3 2026 results.
- ExecutiveJim Pursley
President announcing step‑back from role.

